Next-generation sequencing (NGS), also known as whole-genome sequencing, high-throughput sequencing and massive parallel sequencing, produces and analyses thousands to millions of nucleotide sequences at once. Sequencing systems operate via varying technologies depending on the manufacturer, including sequencing by synthesis, ligation, pyrosequencing, ion semiconductor and single-molecule real-time sequencing. For NGS, library preparation is paramount to successful sequencing. In this section, explore a range of library preparation kits, from targeted, amplicon-based or hybridization-based kits including epigenomic, transcriptomic and genomic workflows to fragmentation kits. Find the best next-generation sequencing products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.
An expanding portfolio of NGS panels for research into haematological and solid tumour cancers, as well as library preparation kits for the accurate detection of a wide range of genetic aberrations
The SureSeq™ Myeloid Plus NGS Complete Workflow combines the rapid Universal NGS Workflow hybridisation-based target enrichment method together with OGT’s expert bait design to detect 49 key genes implicated in myeloid disorders.
The SureSeq™ CLL + CNV Panel has been designed in collaboration with recognised cancer experts to detect 13 key genes and 5 chromosomal regions implicated in CLL progression (Table 1). The SureSeq CLL + CNV Panel alleviates the burden of running multiple assays and streamlines your CLL research to deliver a comprehensive genomic profile for each CLL sample using a single workflow
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases characterised by the overproduction of one or more types of blood cells. The SureSeq™ Core MPN Panel has been designed in collaboration with recognised cancer experts to detect somatic variants in 3 clinically relevant MPN associated genes; JAK2, MPL and CALR.
The complete library preparation solution for unparalleled next generation sequencing (NGS) results. Based on scientists’ feedback, we have redesigned our workflow to ensure scientists achieve the most optimal NGS libraries, with one library preparation workflow across both our SureSeq™ and CytoSure® Constitutional NGS products.
Interpret is OGT’s powerful and easy-to-use next-generation sequencing analysis solution.
LiquidPlex panel is an advanced and user-friendly research assay for targeted next generation sequencing of circulating cell-free tumor DNA (ccfDNA/cfDNA/ctDNA) from 28 genes commonly associated with solid tumor type cancers.
FusionPlex Lung v2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 17 genes associated with NSCLC.
FusionPlex Core Solid Tumor is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 57 genes associated with various solid tumor malignancies.
FusionPlex Core Solid Tumor is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 57 genes associated with various solid tumor malignancies.
FusionPlex Pan Solid V2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 137 genes associated with various solid tumor malignancies.
VariantPlex Solid Tumor Focus V2 is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and MSI from 20 genes associated with various solid tumor malignancies.
VariantPlex Core Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and MSI from 60 genes associated with various solid tumor malignancies.
VariantPlex Expanded Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and MSI from 76 genes associated with various solid tumor malignancies.
VariantPlex Pan Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, MSI, and TMB from 185 genes associated with various solid tumor malignancies.
VariantPlex Complete Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, MSI, and TMB from 430 genes associated with various solid tumor malignancies.
Immunoverse is a research assay that characterizes the immune repertoire, including assessment of T- and B-cell clonalities and rare clones, and detection of tumor infiltrating lymphocytes (TIL) and somatic hypermutation with targeted NGS of key T cell receptor and B cell receptor chain RNA relevant for blood cancer and solid tumor research.
VariantPlex Myeloid is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and ITDs from 75 genes associated with acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS).
VariantPlex Core Myeloid is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and ITDs from 37 genes associated with acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS).
FusionPlex Pan Heme is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 199 genes associated with lymphoid and myeloid malignancies.
FusionPlex Heme V2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 87 genes associated with lymphoid and myeloid malignancies.
FusionPlex Myeloid is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 84 genes associated with myeloid-origin malignancies.
FusionPlex Lymphoma is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 125 genes associated with lymphomas.
FusionPlex ALL is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 81 genes associated with acute lymphoblastic leukemia (ALL) .
As the framework of stellar automation, Nucleus® Automation Infrastructure combines (A) your choice of stationary or mobile mounted collaborative robotic arms; (B) mobile cart or stationary table work surfaces to house your preferred devices; and (C) powerful Cellario™ Whole Lab Automation software. Unique MicroDock technology lets you effortlessly roll workflow devices in and out for space efficiency and manual device use.
